“This study shows that daratumumab added to KRd is a new standard of care for those patients who had previously been candidates for just KRd,” said C. Ola Landgren, M.D., Ph.D., director of the ...
Genetically modified immune cells can offer precious additional time to patients with advanced multiple myeloma. However, these therapies lose their impact as the molecules on cancer cells that immune ...
The study evaluated the efficacy and safety of the investigational immunotherapy combination of TECVAYLI ® plus DARZALEX FASPRO ® versus DARZALEX FASPRO ® and dexamethasone with either pomalidomide or ...
Jaime Suarez-Londono, MD: Transplant for myeloma is very easy to give. On day 12 they engraft and they go home. Adverse events are not that [severe], and they get this progression-free survival [PFS] ...
A new study maps the immune cell landscape of bone marrow in patients with multiple myeloma, a rare cancer that develops in the plasma cells of the bone marrow and has no cure. This large immune cell ...
"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...
Darzalex Faspro is approved for high-risk smoldering multiple myeloma, showing significant efficacy in delaying disease progression. The AQUILA trial demonstrated a 51% reduction in the risk of ...
Newly diagnosed multiple myeloma patients at Sylvester and other cancer centers are already routinely receiving the four-drug DKRd combination. "It has definitely changed my practice," said Sylvester ...
ORLANDO, Fla., Dec. 9, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ), the worldwide leader in multiple myeloma, today announced new data from the investigational Phase 3 MajesTEC-3 study that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results